Genmab — December 2019

[Solsen]

https://twitter.com/andrew02114/status/1203340313248632833 Hvad mon dette er...

[Solsen]

BCMAxCD3 https://www.onclive.com/conference-coverage/ash-2019/anti-bcma-cd3-agent-cc-93269-shows-promise-for-heavily-pretreated-myeloma/

[Bulder]

Eller her: https://ash.confex.com/ash/2019/webprogram/Paper122895.html

[Bulder]

Det er også det Nina Shah taler om 3 min inde https://www.youtube.com/watch?v=6pbWhqladhQ&feature=youtu.be

[Solsen]

Flotte data, men SAE kan være et problem. Godt nok spændende hvad Genmabs CD3 arm kan.

[Solsen]

Vi fandt vel aldrig ud af om det er den berømte silenced arm, der benyttes i JNJs duobodies ?

[Bulder]

Det er det vist ikke. Og det er fc-delen der bliver "silenced". Winkel skrev sidste år på q&a: You are referring to the way we have "silenced" the Fc-part of this bispecific. This has
been done in a novel manner with the intent of lessening interactions with immune
cells, resulting in less/absent non-specific activation of immune killer cells. This should
result in better safety.

[Bulder]

Det var om cd3xcd20.

[Bulder]

Der er mange der arbejder med silencing af fc-regionen. Både for at styrke effekten og for (som i genmabs tilfælde) at mindske bivirkninger. Hvis man googler "silencing fc-domaine" får man masser af hits.

[Solsen]

Blev der ikke spurgt direkte til om det var denne arm JNJs duobodies havde. Mener at huske han svarede at han ikke kunne afsløre det. Men ikke sikkert, at min hukommelse er god nok -:)

[Bulder]

Denne her "novel manner" kunne tyde på at Genmab har fundet på noget særligt.

[Solsen]

Ja. Det bliver spændende.

[Bulder]

Til gengæld har både PD-L1x4-1BB og CD40x4-1BB en form for silenced fc-domæne. Sikkert det samme som cd3xcd20. De har i hvert fald conditional T-cell activation.

[Helge_LarsenPI-redaktør]

Go morgen.

[Helge_LarsenPI-redaktør]

Update on MAIA study also provided as a poster. PFS still very good 68%) at 3 years. Even with Rd it was a median of 34. Effect of risk less clear on this dataset, although lower numbers.
https://twitter.com/Rfonsi1/status/1203433426101125120

[Helge_LarsenPI-redaktør]

Rafael Fonseca MD
@Rfonsi1
·
7 t
KEY PAPER. Updated FU on POLUX presented by @kaufman_MMdoc
. After a median FU of 59 months the median PFS reported at 45 months. Interestingly TTNT not reached after 63 months. https://twitter.com/Rfonsi1/status/1203437275213967377

[Helge_LarsenPI-redaktør]

The Debate Heats Up Over Treating High Risk Smoldering Multiple Myeloma
https://paper.li/Myeloma_Doc/1310386431?read=https%3A%2F%2Fwww.myelomacrowd.org%2Fash-2019-the-debate-heats-up-over-treating-high-risk-smoldering-multiple-myeloma%2F

[bibob]

https://www.onclive.com/conference-coverage/ash-2019/antibcma-cart-jnj4528-hits-100-response-rate-in-heavily-pretreated-myeloma?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==&utm_medium=email&utm_campaign=ONCSS Conference Coverage ASH Global c360 eNews Yescarta Gilead 12-7-19&utm_content=ONCSS Conference Coverage ASH Global c360 eNews Yescarta Gilead 12-7-19+CID_5e6bb120d3a26928c3d6391e76a23ac4&utm_source=CM ONCLIVE&utm_term=Anti-BCMA CAR-T JNJ-4528%2

[bibob]

Landgren previews pivotal ASH 2019 Myeloma data. https://www.onclive.com/conference-coverage/ash-2019/landgren-previews-pivotal-ash-2019-myeloma-data

[Sukkeralf]

https://www.firstwordpharma.com/node/1686169?tsid=1